PTP1B inhibitors with insulin-like activity are extremely rare, and, thus, we are now investigating the optimal structures for these biological properties with the aim of developing candidate agents for the treatment of T2DM and obesity. The gene discussed is PTPN1; the disease is type 2 diabetes mellitus.